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Two HLA-A*02-restricted epitopes have been identified within the VP1 polypeptide of a human polyomavirus, BK virus, which is associated
with polyomavirus-associated nephropathy in kidney transplant patients. Immunization of transgenic mice with recombinant modified vaccinia
Ankara expressing BKV VP1 (rMVA-BKV VP1) elicited functional CTL populations recognizing the sequences LLMWEAVTV (amino acids
residues 108–116, BKV VP1p108) and AITEVECFL (residues 44–52, BKV VP1p44) and cross-reactive to the previously described JC virus
VP1 homologs. Flow-based analyses of PBMC from a panel of thirty healthy HLA-A*02 human volunteers indicated that the majority of these
subjects harbored functional CTL populations recognizing the BKVepitopes and cross-reactive with the JCV homologs. CTL recognizing the JCV
VP1p100 and JCV VP1p36 epitopes have previously been associated with prolonged survival in progressive multifocal leukoencephalopathy
patients. These findings suggest that infection with BKV or JCV could potentially induce cross-protective T-cell immunity against diseases
associated with these viruses.
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The polyomaviruses BK virus (BKV) and JC virus (JCV)
infect the majority of humans early in life and establish
asymptomatic persistent infection in the kidney as well as other
tissues (Chesters et al., 1983). The two viruses are closely
related (∼70% sequence homology), and both reactivate in the
context of immune suppression. BKV reactivation in recipients
of hematopoietic stem cell transplantation (HSCT) or kidney
transplantation (KTx) is evidenced by viruria and/or viremia. In⁎ Corresponding author. Room 1001C, Fox South Bldg., Laboratory of
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doi:10.1016/j.virol.2006.02.040a minority of individuals, BKV can cause clinical disease
including hemorrhagic cystitis, ureteric stenosis and BK-virus-
associated nephropathy (BKVN), which is associated with
significant morbidity and mortality in KTx patients. JCV
reactivation is associated with progressive multifocal leukoen-
cephalopathy (PML), a fatal demyelinating disease of the CNS
seen in immunocompromised patients with AIDS, cancer or
recipients of organ transplantation. Two T-cell epitopes have
been identified within the JCV major capsid protein VP1, and
CTL recognizing these epitopes have been associated with
control of the virus (Du Pasquier et al., 2004a, 2004b). Recently,
PML has been identified as a complication of natalizumab
treatment of patients with multiple sclerosis (Kleinschmidt-
DeMasters and Tyler, 2005) and Crohn's disease (Langer-Gould
et al., 2005), with a temporal association shown between serum
JCV load and natalizumab therapy. Natalizumab is a humanized
monoclonal antibody against α4 integrins, and it is probable
that, by blocking normal trafficking of lymphocytes, this drug
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important in control of PML in HIV+ patients (Du Pasquier et
al., 2004a, 2004b).
Since BKVand JCVare so closely related, it seems probable
that T-cell responses are also important in control of BKV. The
incidence of BKVN in KTx recipients has increased in recent
years due to the use of newer and more potent immunosup-
pressive agents, and the primary treatment options for BKVN
are judicious reduction of immunosuppression and experimen-
tal use of cidofovir. Early studies of T-cell immunity to BKV
used BKV-infected cell lysates as antigens and did not define
specific antigens or epitopes recognized by the immune system
(Comoli et al., 2003, 2004; Drummond et al., 1985, 1987). The
first T-cell epitope to be described for BK virus, an HLA-A*02-
restricted epitope, LLMWEAVTV at position 108–116 within
the BKV VP1 major capsid protein was identified as a candidate
epitope by using computer predictions of HLA binding and
shown to be generated by in vivo processing of the full-length
BKV VP1 polypeptide in a transgenic mouse model (Kryms-
kaya et al., 2005) (Table 1). CTL populations recognizing this
epitope and cross-reacting with the JCV homolog epitope
ILMWEAVTL (position 100–108 in the JCV VP1 ORF) were
shown to be present in a small group of normal human subjects
and in a kidney transplant (Ktx) recipient expressing the HLA-
A*02 phenotype (Krymskaya et al., 2005). In the present study,
we identify a second HLA-A*02-restricted epitope within the
BKV VP1 ORF and show that CTL recognizing this epitope
also frequently cross-react with the JCV homolog. We have
surveyed a panel of thirty healthy individuals expressing HLA-
A*02 for the presence of CTL recognizing these four
polyomavirus epitope sequences and characterized these CTL
in terms of their function and phenotype after expansion in
culture.
Results
Identification of a HLA-A*02-restricted T-cell epitope within
the BKV VP1 polypeptide by use of a transgenic mouse model
An HLA-A*02-restricted T-cell epitope SITEVECFL has
previously been reported at position 36–44 within the JCV VP1
(Du Pasquier et al., 2003, 2004a, 2004b). The BKV sequence at
position 44–52, AITEVECFL differs from the JCV homolog
only at the N-terminal amino acid residue (Table 1), leading us
to speculate that the BKV VP1p44–52 sequence might
represent a functional CTL epitope. We immunized HHDII
transgenic mice intraperitoneally with a recombinant modified
vaccinia Ankara (MVA) expressing BKV VP1. Two weeksable 1
lignment of BKV and JCV VP1 T-cell epitope homologs
on-conserved amino acid residues are highlighted.T
A
Nfollowing immunization, the mice were sacrificed, the spleens
harvested and the splenocytes stimulated for 2 weeks in culture
with the BKV VP1p44–52 peptide. Following this stimulation,
the splenocytes were tested for their ability to lyse Jurkat A2
cells pulsed with the BKV VP1p44–52 peptide, or the JCV
VP1p36–44 peptide, or with an irrelevant HIV peptide. The
results of these experiments (Fig. 1) indicated that the murine
effector cells recognized target cells presenting the BKVand the
JCV homologs of this epitope with similar affinity. BKV VP1
polypeptide is therefore processed in vivo in these transgenic
mice to generate the p44–52 epitope and elicit a T-cell response
restricted by HLA-A2.
Cytotoxic T-cells that cross-recognize the BKV VP1p44–52 and
JCV VP1p36–44 epitopes are present in a majority of healthy
humans expressing HLA-A2
We then wished to investigate the prevalence in humans of T-
cell populations recognizing the BKV VP1p44–52 and JCV
VP1p36–44 epitopes and to determine whether cross-reactivity
similar to that found in the mouse model would be seen in the
context of human lymphocytes. Aliquots of archival cryopre-
served PBMC samples from healthy human volunteers expres-
sing HLA-A*02 were stimulated for 2 weeks in culture in the
presence of IL-2 with one of the following four peptides: BKV
VP1p44–52 or JCV VP1p36–44 (11 subjects), BKV
VP1p108–116 or JCV VP1p100–108 (25 subjects) before
analysis. VP1-specific CD8+ T-cells were detected by labeling
with a panel of four HLA-A*02 tetramers refolded with the
peptides and conjugated to either phycoerythrin (PE) in the case
of the JCV tetramers or allophycocyanin (APC) in the case of
the BKV tetramers. A cut-off value for positivity was set at
0.2% of CD8+ T-lymphocytes. This threshold was based on
control stainings of these expanded cultures with irrelevant HIV
tetramers (data not shown). Fig. 2A shows representative flow
plots of analyses of PBMC from donor ND#02 that were
expanded by stimulation with BKV VP1p44–52 peptide. The
proportion of cells labeled by the BKV VP1p44 tetramer-APC
was very similar to that labeled by the JCV VP1p36 tetramer-
PE. No staining was seen with an irrelevant HIV tetramer-PE
when used singly or in combination with the BKV VP1p44
tetramer-APC. Moreover, when the cells were double labeled
with both tetramers (Fig. 2A, lower right hand plot, which was
gated on CD8+ lymphocytes), virtually all the tetramer-binding
cells are in the upper-right quadrant, indicating that they were
stained by both tetramers, and cross-recognized both the JCV
VP1p36 and the BKV VP1p44 epitope. This cross-recognition
was seen in most of the eleven subjects investigated for
responses to the JCV VP1p36 and the BKV VP1p44 epitopes
and was seen for T-cell populations expanded by stimulation
with either peptide (Figs. 3A and B). Eight of eleven (73%)
individuals expanded T-cells recognizing BKV/JCV in response
to stimulation with the BKV VP1p44 peptide. Six of eleven
(55%) responded to stimulation with the JCV VP1p36 peptide,
and ten of eleven (91%) responded to at least one of the two
forms of the epitope, while four (36%) responded to both
peptides.
Fig. 1. Cross-reactive T-cell responses recognizing the BKV VP1p44–52 and
JCV VP1p36–44 epitopes in HHDII transgenic mice immunized with rMVA
expressing BKV VP1. Mice were immunized intraperitoneally with 3 × 107 pfu
of rMVA-BKV VP1 and sacrificed 2 weeks later. The spleens were harvested,
and the splenocytes cocultivated with irradiated naive splenocytes pulsed with
BKV VP1p44–52 peptide. After 1 week, the cultures were tested for specific
cytotoxicity versus Jurkat A2 cells pulsed with BKV VP1p44–52 peptide
(squares), or JCV VP1p36–44 peptide (diamonds), or an irrelevant HIV peptide
(triangles). E:T ratio, effector to target ratio. The error bars represent standard
deviations. This figure is representative of three separate experiments.
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A*02 allele for T-cell responses to the BKV VP1p108–116 and
JCV VP1p100–108 epitopes. The frequency of responses to the
BKV VP1p108–116 (5/25 individuals, 20%) and JCV
VP1p100–108 (9/25 individuals, 36%) was lower than that
seen to the p36/p44 epitopes (Figs. 3C and D). Because of
limitations on patient sample availability, we were unable to
investigate all 31 subjects for T-cell responses to each of the four
epitopes. Among the subjects was an individual (ND#26) with
an unusual pattern of responses to the BKV VP1p108–116 and
JCV VP1p100–108 epitope peptides. The primary flow data for
this individual are shown in Fig. 4. Stimulation of this subject's
PBMC with the JCV VP1p100 peptide (but not the BKV
VP1p108 peptide) expanded a population of CD8+ cells that
were bound by the JCV VP1p100 tetramer but did not stain with
the BKVVP1p108 tetramer in single or double tetramer labeling
experiments. In short, this individual, unlike the majority of
subjects in this study with T-cells recognizing polyomaviruses,
harbored a CTL response that was specific for the JCV version of
this epitope and did not cross-react with the BKV epitope.
Functionality of T-cells recognizing the BKV VP1p44–52 and
JCV VP1p36–44 epitopes
We investigated the functionality of these CTL populations by
using a combined tetramer, intracellular cytokine and cytotoxic
granule mobilization assay which we have described previously
(Krymskaya et al., 2005). A representative result of such an
experiment on a culture containing a population of CTL
recognizing the p44/p36 epitope is shown in Fig. 2B. The cells
were re-stimulated with the BKV VP1p44–52 peptide before
permeabilization and staining with tetramer and antibodies to CD8,
to IFN-γ and to CD107a/b, a cytotoxic granule marker (Betts et al.,
2003). The cells were gated on CD8+ tetramer-positive cells, and
the levels of intracellular IFN-γ and degree of CD107a/b
mobilization assessed. When these cells were mock-stimulated,
most of the cells were negative for IFN-γ and degranulation, as
shown by their position within the bottom left quadrant of the topright plot in Fig. 2B). Upon stimulation with the BKVVP1p44–52
peptide, approximately 65% of these cells both degranulated and
produced IFN-γ, and another 14%of the cells degranulatedwithout
producing cytokine (bottom right plot in Fig. 2B). These results
suggest that these BKV/JCV VP1-specific cells expanded by
peptide stimulation represent functional CTLs.
BKV/JCV-specific CD8+ T-cells are less differentiated than
CMV-specific T-cells
A putative model of T-cell differentiation has been proposed
(Fig. 6) in which early differentiated cells expressing the costi-
mulatory receptors CD27 and CD28 progress from a CD28+
CD27+ phenotype through to fully differentiated CD28−CD27−
cells. Evidence for this model rests on the correlation of these
markers and telomere length (Effros et al., 1996; Hamann et al.,
1999; Roos et al., 2000). Appay et al. (2002) have reported
patterns of CD27 and CD28 expression associated with CD8+ T-
cells recognizing the human viruses Epstein–Barr virus (EBV,
mostly early CD27+, CD28+), human immunodeficiency virus
(HIV, mostly intermediate CD27+, CD28−), human cytomega-
lovirus (CMV, mostly late CD27−CD28−) and hepatitis C virus
(HCV, mostly early CD28+, CD27+). The frequency of BKV/
JCV-specific CD8+ T-cells in normal volunteers was too low to
permit direct analysis without expansion by stimulation.
However, at least one report indicates that, despite extensive in
vitro proliferation, the CD27 phenotypes of CD8+ T-cell clones
specific for HIV, CMVand EBV were typical of freshly isolated
CD8+ T-cells reactive with these viruses (Ochsenbein et al.,
2004). We therefore analyzed in-vitro-expanded BKV/JCV-
specific CD8+ T-cells by tetramer labeling in combination with
panels of antibodies to the surface markers CD8, CD45RA,
CD45RO, CCR7, CD27, CD28 and the cytotoxic molecules
granzyme A, granzyme B and perforin. As a control, we also
characterized the surface marker phenotype of CMV-specific
cells expanded from PBMC from several of the subjects by
stimulation with peptides corresponding to HLA-A2-restricted
epitopes within the CMV pp65 (NLVPMVATV495–503) and IE-1
(VLEETSVML316–324) polypeptides. The CMV-specific CD8
+
T-cells were predominantly CD27-negative and CD28-negative
(Fig. 5). This is in agreement with our previous studies on CMV-
specific T-cells and with the report of Appay et al. (2002). By
contrast, the BKV/JCV-specific CD8+ T-cells mostly expressed
CD28 as well as CD27. Their CD27/CD28 phenotype was thus
similar to the EBV and HCV-specific T-cells described by
Appay et al. (2002) as being early-differentiated cells (Fig. 6).
Discussion
In this study, we have documented T-cell responses in a
majority of a panel of healthy immunocompetent humans
expressing HLA-A*02 to two T-cell epitopes within the BKV
VP1 polypeptide that are restricted by this MHC-I allele. One of
these epitopes (BKV VP1p44) has not, to our knowledge, been
described before. In most cases, T-cells recognizing these
epitopes cross-recognized cells presenting the JCV homolog
peptide.
Fig. 2. Cross-reactivity and functionality of CD8+ T-cells in human samples recognizing the BKV VP1p44–52 and JCV VP1p36–44 epitopes. (A) PBMC from a
normal subject were stimulated for 11 days in culture with BKV VP1p44–52 peptide in the presence of rIL2 before tetramer staining and flow analysis. In the upper
row of plots, the cultures were labeled with FITC-conjugated antibody to CD8, and with BKV VP1p44 tetramer conjugated to APC, or with JCV VP1p36 tetramer
conjugated to PE, or with an irrelevant HIV-PE tetramer. In the lower row of plots, the cells were labeled simultaneously with two tetramers. All plots were gated on
lymphocytes as assessed by forward and side scatter. (B) Interferon-γ production and CD107a/b mobilization by BKV VP1p44 tetramer-binding CD8+ T-cells.
Aliquots of the culture shown in panel Awere mock-stimulated (upper row) or stimulated with BKV VP1p44–52 peptide (lower row) for 6 h before labeling and flow
analysis. The right-hand column of plots is gated on CD8+ and tetramer+ lymphocytes (boxes within left plots). The numbers within the quadrants indicate events as a
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overall seroprevalence in a large number of studies measuring
neutralizing antibody titer or hemagglutination ranged between
50% and 90% in populations of healthy individuals or
unselected patient groups (for a review, see Knowles, 2001).
One recent study of 2435 sera in the UK reported an age-related
BKV seroprevalence of 91% by the age of 5–9 but a JCV
seroprevalence rate of only 50% by the age of 60–69 (Knowleset al., 2003). In addition, some molecular studies on leukocytes
have suggested that almost all immunocompetent adults are
infected with both BKV and JCV (Dorries et al., 1994). Given
the probability that the majority of adult volunteers in our study
cohort had been exposed to BKV and/or JCV, and not
anticipating the high degree of T-cell immunity cross-reactivity
that we observed, we did not screen sera from our subjects for
BKV serostatus.
Fig. 4. Specificity of CTL in subject ND#26 for the JCVVP1p100–108 epitope. IVS with the BKVVP1p108–116 peptide did not expand tetramer-binding CD8+ cells
from subject ND#26 PBMC (left column of plots). However, stimulation of ND#26 PBMC with the JCV VP1p100–108 peptide expanded a population of cells that
were bound by the JCV VP1p100–108 tetramer but not by the BKV VP1p108–116 tetramer (center and right plots).
Fig. 3. CD8+ T-cell responses in normal humans to the BKV and JCV homologs of two HLA-A*02-restricted epitopes within the VP1 capsid proteins. Archival
cryopreserved PBMC from thirty normal human subjects expressing the HLA-A*02 allele were examined by peptide IVS followed by tetramer assay of the cultures for
CTL responses to four polyomavirus epitopes. Panels A and B: BKV VP1p44–52 and JCV VP1p36–44 (11 subjects). Panels C and D: BKV VP1p108–116 and JCV
VP1p100–108 (25 subjects). Light bars on all charts indicate percent of CD8+ T-cells binding BKV tetramers and dark bars the percent binding JCV tetramers.
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Fig. 5. Differences in differentiation phenotype between CMV-specific and BKV/JCV-specific CD8+ T-cells in normal subjects. CD8+ T-cells expanded from subject
PBMC by stimulation with the HLA-A*02-restricted CMV IE-1p316-324 peptide (left column) or with the BKV VP1p44–52 peptide (center and right columns) were
labeled with the cognate tetramer and CD28-PE and CD27-FITC antibodies. The bottom row of plots was gated on CD8+ and tetramer+ lymphocytes.
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response to the JCV VP1p100 epitope that was unusual in this
cohort for its specificity; attempts to expand T-cells from this
individual by stimulation with the BKV VP1p108 peptide were
unsuccessful, and the cells expanded by stimulationwith the JCV
VP1p100 peptide did not bind the BKV VP1p108 tetramer. It is
therefore probable that these JCV-specific memory T-cells were
in fact elicited in response to JCV VP1 antigenic stimulation,
although the reason for lack of cross-reactivity in this case is
unclear. This individual could have been infected with a JCVFig. 6. Hypothetical model for CD8+ T-cell differentiation, with accumulation of
virus-specific T-cells at different stages according to the distinct properties of the
infections. This model is based on the studies of Appay and colleagues on EBV,
CMV and HCV-specific T-cells (Appay et al., 2002) modified to include our
observations on CMVand BKV/JCV-specific CTL surface marker phenotypes.strain with one or more sequence alterations within the region of
the VP1 sequence corresponding to the p100 epitope, such that it
diverged further from the BKV sequence, thus preventing cross-
recognition of the BKV p108 peptide while retaining enough
homology with the archetypical JCV sequence ILMWEAVTL to
allow recognition. However, a BLAST search of VP1 sequences
indicated that all JCV VP1 sequences described to date are
completely conserved within the p100 epitope. An alternative
hypothesis is that the structure of the T-cell receptor (TCR) of the
JCV VP1p100-specific CD8+ T-cell population within subject
ND#26 had some character that decreased the promiscuity of
cross-recognition of close homologs of the JCV VP1p100
epitope relative to the TCRs on the corresponding T-cells in
subjects ND#02, ND#03, ND#21, ND#27, ND#30 and ND#31
that exhibited p100/p108 cross-reactivity.
This concept has been explored by others in the context of
murine responses to the related lymphocytic choriomeningitis and
Pichinde viruses. A complex pattern of T-cell cross-reactivity was
found that depended in part on the specificity of private T-cell
repertoires of individual mice (Lin and Welsh, 1998; Kim et al.,
2005). An example of observed differences in T-cell cross-
reactivity between human subjects has been reported in the
context of cells recognizing related influenza and Epstein–Barr
virus epitopes and attributed to the private specificity of individual
TCR repertoires (Clute et al., 2005). In short, there is ample
precedent for the concept that individuals' T-cells may differ in
their degree of cross-reactivity to two closely related epitopes.
Our finding of an early-differentiated (CD27+, CD28+)
phenotype of BKV/JCV-specific as compared to CMV-specific
(CD27−, CD28−) CD8+ T-cells based on expression of these
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viruses and the functional properties of the T-cell phenotype
needed during chronic infection. The subjects in this study were
healthy immunocompetent individuals chronically infected with
JCVor BKVor both. It may be speculated that, in subjects with
active BKV infection (PVAN) or JCV infection (PML), the
polyomavirus-specific CD8+ T-cells having been more recently
exposed to antigen in vivo would be driven down the pathway
to late differentiation (CD27−, CD28−). CMV has evolved
immunoevasive strategies that by encoding several gene
products including US2, US3, US6 and US11, may interfere
with MHC class I presentation (Jones et al., 1996; Wiertz et al.,
1996; Jones and Sun, 1997; Ahn et al., 1997). CMV also
encodes a homolog of human IL-10 cytokine (Kotenko et al.,
2000), which may modulate the cytokine environment for T-cell
differentiation. The polyomaviruses have a far smaller genome
compared to the herpesviruses, but it is clear that the large T
antigen and the agnoprotein, at least, modulate the host cell
processes by affecting transcription and cell cycle. The net
result of these viral and host cell interactions may be to cause
accumulation of T-cells at distinct steps on the differentiation
pathway that reflect the nature and properties of the virus in
question (Fig. 6).
In this report, we have shown that low-level T-cell responses
recognizing two HLA-A*02-restricted BKV epitopes within
VP1 are present in a majority of healthy immunocompetent
individuals expressing this HLA type. The knowledge of these
epitopes allows the design and use of immunologic tools such as
peptides and MHC-I tetramers for tracking of immune
responses to these epitopes in populations such as kidney
transplant recipients at risk for BKV reactivation and develop-
ment of PVAN. Given the high homology between BKV and
JCV, the cross-reactivity of these epitopes demonstrated in this
report and the previous finding that CTL recognizing the JCV
homologs are protective from the JCV-associated syndrome
PML (Du Pasquier et al., 2001, 2004a, 2004b; Koralnik et al.,
2002), it is highly likely that CTL recognizing the BKVepitopes
will be associated with protection against PVAN. It will be of
great interest to determine the immunological circumstances in
which approximately 5% of KTx recipients develop PVAN.
Presumably, this is due to a failure of T-cell-mediated immune
control, and this is the subject of our ongoing investigations.
Materials and methods
Study subjects
PBMCwere collected from thirty healthy HLA-A*02 donors
at City of Hope and cryopreserved by standard methods
(Maecker et al., 2005). These cryopreservation procedures do
not normally significantly impact immunological assays
(Maecker et al., 2005). The study protocol was approved by
the COH Institutional Review Boards, and specimens and data
were obtained prospectively after obtaining informed consent
from the enrollees. HLA typing was performed by PCR, as
described elsewhere (Krausa and Browning, 1996) for all blood
donors.Peptides
Peptides were synthesized in our laboratory with a
Symphony Quartet peptide synthesizer (Protein Technologies
Inc., Tucson, Arizona) using standard FMOC protocols and
purified to >95% purity by HPLC. The identity of the peptides
was confirmed by MALDI TOF mass spectrometric analysis
using a Kompact Probe mass spectrometer (Kratos Analytical,
Shimadzu, Kyoto, Japan).
Tetramer construction
The HLA-A*02 BKV VP1p108, HLA-A*02 JCV
VP1p100, HLA-A*02 BKV VP1p44, HLA-A*02 JCV
VP1p36 and HLA-A*02 CMV IE-1 316–324 tetramers
were refolded, purified and conjugated to fluorochromes in
our laboratory using previously described methods (La Rosa
et al., 2002).
rMVAs expressing BKV VP1
The preparation of this rMVA (rMVA-BKV VP1) has
been described previously (Krymskaya et al., 2005).
Immunization of Tg mice and in vitro expansion of CTLs
The transgenic mouse strain HHDII was obtained from
Dr. F. Lemonnier (Pasteur Institute) (Firat et al., 1999). This
mouse expresses a transgenic monochain histocompatibility
class I molecule in which the C-terminus of the human
β2m is covalently linked to the N-terminus of a chimeric
heavy chain (HLA-A*0201-α1, -α2, H-2Db-α3-transmem-
brane and intracytoplasmic domains). The colony of HHDII
mice used in this study was seronegative for murine
polyomavirus as shown by regular testing by MFI
(multiplex fluorescent immunoassay) at the University of
Missouri Research Animal Diagnostic Laboratory. Eight- to
twelve-week-old mice were immunized intraperitoneally
with 3 to 5 × 107 pfu of rMVA-BKV VP1. The animals
were sacrificed after 2 weeks and the spleens retrieved.
Single-cell splenocyte suspensions were prepared by passing
the cells through a 70-μm Falcon cell strainer (Becton
Dickinson Labware, Franklin Lakes, NJ) using the plunger
from a sterile 1-ml syringe. Splenocytes were subjected to 1
round of in vitro expansion (IVS) as previously described
(La Rosa et al., 2002). Briefly, splenocytes from immunized
animals were cocultured with peptide-loaded LPS blasts in
complete IVS medium at a ratio of 3:1 for 7 days, with the
addition of 10% rat T-stim (Collaborative Biomedical
Products, Bedford, MA).
Cytotoxicity assay
Cytolytic activity of effector cell populations was determined
using a 4 h chromium release assay (CRA) following 1 IVS, as
previously described (La Rosa et al., 2001; Daftarian et al.,
2003). Jurkat A2.1 cells pulsed with 10 μM of the relevant or
control HIV peptides were used as targets for CRA. Jurkat A2.1
cells were loaded with 200 μCi of Na51 CrO4
− (ICN, Costa
Mesa, CA) for 1 h in a 37 °C water bath and further processed as
described (La Rosa et al., 2001). Experimental evaluations were
performed in triplicate.
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Splenocytes after 1 week IVS stimulation were tested for
intracellular IFN-γ production by stimulation overnight with
5 μMBKVor JCV peptides. The following day, brefeldin Awas
added to all the cultures and incubation continued for 4 h. The
cells were then washed with 3 ml PBS/0.5% BSA before
labeling for 20 min at 4 °C with an FITC-conjugated antibody to
murine CD8 (Pharmingen). The cells were then washed again
with PBS/0.5% BSA before permeabilization (Cytofix/Cyto-
perm, Pharmingen) and labeling with APC- or PE-conjugated
antibody to IFN-γ for 30 min at 4 °C. The cells were washed
and analyzed on a FACSCanto flow cytometer (Becton
Dickinson).
In vitro stimulation of PBMC
Cryopreserved human PBMCwere cultured in 24-well tissue
culture plates at a density of 3.5 million/ml in RPMI 10
containing 1 μg/ml of a single BKVor JCV VP1 peptide at 37
°C in a CO2-gassed incubator. After 3 days, recombinant human
IL-2 (NIH AIDS Research and Reference Reagent Program)
was added to 30 units/ml. Each 2 days thereafter, 50% of the
culture medium was removed and replaced by fresh medium
containing rIL2. Incubation was continued for 11–14 days
before flow analysis.
Combined ICC and CD107 mobilization/degranulation assay
This assay was performed essentially as previously
described (Betts et al., 2003). Aliquots of 1 million cells
from in vitro stimulation cultures were resuspended in 1 ml of
RPMI 10 medium and FITC-conjugated antibodies to CD107a
and CD107b (Pharmingen) added followed by costimulatory
antibodies to CD28 and CD49d (Pharmingen) to 1 μg/ml each.
Antigenic peptides corresponding to those incorporated in the
tetramers or irrelevant peptides as controls were then added to
some of the tubes to a final concentration of 5 μM. Monensin
(1 μl, ‘GolgiStop’, Pharmingen) was added to all the tubes
before incubation at 37 °C in a gassed incubator for 5 h. The
cells were then labeled for 20 min at 4 °C with APC-
conjugated tetramers followed by 20 min with PerCP-
conjugated antibody to CD8 (Pharmingen) before permeabili-
zation (Cytofix/Cytoperm, Pharmingen) and labeling with PE-
conjugated antibody to IFN-γ (Pharmingen) for 30 min at 4 °C
before flow analysis. A primary gate was set on lymphocytes
using forward and side scatter and a secondary gate set on
CD8+ tetramer-binding cells. At least 100,000 events were
collected per sample. The percentage of CD8+ tetramer-
binding lymphocytes expressing elevated surface CD107a/b
and secreting IFN-γ was determined by reference to controls
incubated with costimulatory antibodies to CD28 and CD49d
but no peptides.
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